EYLEA 2 mg is indicated for adults for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).

PROACTIVE DOSING WITH EYLEA 2 mg

Adapted from EYLEA 2 mg Summary of Product Characteristics.

EYLEA 2 mg posology in macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)

The recommended dose for EYLEA is 2 mg aflibercept equivalent to 0.05 mL. After the initial injection, treatment is given monthly. The interval between two doses should not be shorter than 1 month. If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, EYLEA should be discontinued. Monthly treatment continues until maximum visual acuity is achieved and/or there are no signs of disease activity. Three or more consecutive, monthly injections may be needed. Treatment may then be continued with a treat-and-extend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes; however, there are insufficient data to conclude on the length of these intervals. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. The monitoring and treatment schedule should be determined by the treating physician based on the individual patient’s response. Monitoring for disease activity may include clinical examination, functional testing or imaging techniques (e.g. optical coherence tomography or fluorescein angiography).

Abbreviations

BRVO, branch retinal vein occlusion. CRVO, central retinal vein occlusion. DMO, diabetic macular oedema. mCNV, myopic choroidal neovascularisation. nAMD, neovascular age-related macular degeneration. RVO, retinal vein occlusion.

Footnote

*The diagram is for illustrative purposes only.